ROACTEMRA 20mg/ml Koncentrat za rastvor za infuziju Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

roactemra 20mg/ml koncentrat za rastvor za infuziju

"hoffmann-la roche ltd" d.s.d. podgorica - tocilizumab - koncentrat za rastvor za infuziju - 20mg/ml

ROACTEMRA 20mg/ml Koncentrat za rastvor za infuziju Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

roactemra 20mg/ml koncentrat za rastvor za infuziju

"hoffmann-la roche ltd" d.s.d. podgorica - tocilizumab - koncentrat za rastvor za infuziju - 20mg/ml

ROACTEMRA 20mg/ml Koncentrat za rastvor za infuziju Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

roactemra 20mg/ml koncentrat za rastvor za infuziju

"hoffmann-la roche ltd" d.s.d. podgorica - tocilizumab - koncentrat za rastvor za infuziju - 20mg/ml

Carvykti Europska Unija - hrvatski - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multipli mijelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Tecartus Europska Unija - hrvatski - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Yescarta Europska Unija - hrvatski - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Kymriah Europska Unija - hrvatski - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Abecma Europska Unija - hrvatski - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Breyanzi Europska Unija - hrvatski - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

LUNSUMIO 1mg Koncentrat za rastvor za infuziju Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

lunsumio 1mg koncentrat za rastvor za infuziju

"hoffmann-la roche ltd" d.s.d. podgorica - mosunetuzumab - koncentrat za rastvor za infuziju - 1mg